Kofink, Christiane http://orcid.org/0000-0003-2515-8843
Trainor, Nicole http://orcid.org/0000-0002-3758-9969
Mair, Barbara http://orcid.org/0000-0001-6982-2529
Wöhrle, Simon http://orcid.org/0000-0002-2478-7333
Wurm, Melanie http://orcid.org/0000-0002-2317-6952
Mischerikow, Nikolai
Roy, Michael J. http://orcid.org/0000-0003-0198-9108
Bader, Gerd http://orcid.org/0000-0002-8410-3415
Greb, Peter
Garavel, Géraldine
Diers, Emelyne
McLennan, Ross http://orcid.org/0000-0001-8125-7702
Whitworth, Claire
Vetma, Vesna http://orcid.org/0000-0003-4013-6917
Rumpel, Klaus http://orcid.org/0000-0002-6755-0985
Scharnweber, Maximilian
Fuchs, Julian E. http://orcid.org/0000-0003-4322-9481
Gerstberger, Thomas http://orcid.org/0000-0002-6837-1401
Cui, Yunhai http://orcid.org/0000-0003-4969-072X
Gremel, Gabriela
Chetta, Paolo
Hopf, Stefan http://orcid.org/0000-0001-7930-9526
Budano, Nicole http://orcid.org/0000-0001-8749-0759
Rinnenthal, Joerg
Gmaschitz, Gerhard
Mayer, Moriz
Koegl, Manfred
Ciulli, Alessio http://orcid.org/0000-0002-8654-1670
Weinstabl, Harald http://orcid.org/0000-0003-1308-2730
Farnaby, William http://orcid.org/0000-0001-8610-932X
Article History
Received: 2 March 2022
Accepted: 15 September 2022
First Online: 10 October 2022
Competing interests
: The authors declare the following competing financial interests: The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista therapeutics, Boehringer Ingelheim, Eisai, Merck KGaA, Nurix therapeutics, Ono Pharmaceuticals and Tocris-Bio-Techne. A.C. is a scientific founder, shareholder and consultant of Amphista therapeutics, a company that is developing targeted protein degradation therapeutic platforms. C.K., B.M., S.W., M.W., N.M., G.B., P.G., G.Ga., K.R., M.S., J.E.F., T.G., Y.C., G.Gr., P.C., S.H., N.B., J.R., G.Gm., M.M., M.K. and H.W. are current or former employees of Boehringer Ingelheim. S.W. is now an employee of Merck; E.D. is now an employee of Astra Zeneca. The remaining authors declare no competing interests.